Inhibrx Biosciences Inc.

06/03/2026 | Press release | Distributed by Public on 06/03/2026 14:02

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.
The 2026 Annual Meeting of Stockholders (the "Annual Meeting") of Inhibrx Biosciences, Inc. (the "Company") was held on June 3, 2026 at 10:00 a.m. Pacific Time online in a virtual format. Of the Company's 14,607,286 shares of common stock issued and outstanding and entitled to vote as of the record date of April 7, 2026, a quorum of 11,541,232 shares, or approximately 79% of the outstanding shares entitled to vote, was present virtually or represented by proxy. Each of the matters set forth below is described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 23, 2026. The following actions were taken at the Annual Meeting:
Proposal 1
Election of the following nominees as Class II directors of the Company, nominated by the Company's Board of Directors (the "Board of Directors"), each to serve until the 2029 Annual Meeting of Stockholders and until their respective successor is duly elected and qualified, or until their respective earlier death, resignation, or removal.
Votes For Votes Withheld Broker Non-Votes
Douglas G. Forsyth 7,608,469 1,463,474 2,469,289
Kimberly Manhard 9,035,097 36,846 2,469,289
Proposal 2
Ratification of the appointment by the Audit Committee of the Board of Directors of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
Votes For Votes Against Votes Abstained
11,510,478 30,347 407
Inhibrx Biosciences Inc. published this content on June 03, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 03, 2026 at 20:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]